Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ViiV’s Potential HIV Blockbuster Among Latest Drugs To Win EMA Nod

Executive Summary

A total of 13 new drugs have been recommended for pan-EU approval, while one has failed to meet the European Medicines Agency’s standards.

You may also be interested in...



GW Pharma's Cannabinoid Medicine Epidyolex Among CHMP Hopefuls

Seven new medicines, including GW Pharma's orphan cannabidiol product, Epidyolex, are due for an opinion from the European Medicines Agency this week on whether they should be recommended for pan-EU approval.

EU Ultomiris Approval Rounds Off A Good Week For Alexion’s Complement Franchise

A first EU approval for Ultomiris added to a label expansion for Soliris in the US made for a good seven days for Alexion’s C5 product portfolio.

ViiV's Dovato Could Challenge Status Quo In Naive EU HIV Patients

The approval of ViiV’s new once-daily, two-drug single-pill for HIV/AIDS could lead to a tough battle in Europe with established therapies.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS125195

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel